Rapid cloning-free mutagenesis of new SARS-CoV-2 variants using a novel reverse genetics platform
eLife · 21.11.2023 · 12
DOI: 10.7554/elife.89035 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 21.11.2023. Verfasst von Enja Tatjana Kipfer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innosuisse - Schweizerische Agentur für Innovationsförderung, University Hospital Basel / Canton BS and RocketVax.
Abstract (Originalsprache)
Reverse genetic systems enable the engineering of RNA virus genomes and are instrumental in studying RNA virus biology. With the recent outbreak of the coronavirus disease 2019 pandemic, already established methods were challenged by the large genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Herein we present an elaborated strategy for the rapid and straightforward rescue of recombinant plus-stranded RNA viruses with high sequence fidelity using the example of SARS-CoV-2. The strategy called CLEVER (CLoning-free and Exchangeable system for Virus Engineering and Rescue) is based on the intracellular recombination of transfected overlapping DNA fragments allowing the direct mutagenesis within the initial PCR-amplification step. Furthermore, by introducing a linker fragment – harboring all heterologous sequences – viral RNA can directly serve as a template for manipulating and rescuing recombinant mutant virus, without any cloning step. Overall, this strategy will facilitate recombinant SARS-CoV-2 rescue and accelerate its manipulation. Using our protocol, newly emerging variants can quickly be engineered to further elucidate their biology. To demonstrate its potential as a reverse genetics platform for plus-stranded RNA viruses, the protocol has been successfully applied for the cloning-free rescue of recombinant Chikungunya and Dengue virus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.
- BioEM Lab, Biozentrum, University of Basel, Mattenstrasse, Basel, Switzerland.
ORCID-Profile: Enja Tatjana Kipfer, David Hauser, Martin J Lett, Fabian Otte, Lorena Urda, Yuepeng Zhang, Mohamed Chami, Christian Mittelholzer, Thomas Klimkait
Förderung
- Innosuisse - Schweizerische Agentur für Innovationsförderung
- University Hospital Basel / Canton BS and RocketVax
Zitieren
APA
Kipfer, E. T., Hauser, D., Lett, M. J., Otte, F., Urda, L., Zhang, Y., Lang, C. M. R., Chami, M., Mittelholzer, C., & Klimkait, T. (2023). Rapid cloning-free mutagenesis of new SARS-CoV-2 variants using a novel reverse genetics platform. eLife, 12. https://doi.org/10.7554/elife.89035
Vancouver
Kipfer ET, Hauser D, Lett MJ, Otte F, Urda L, Zhang Y, et al. Rapid cloning-free mutagenesis of new SARS-CoV-2 variants using a novel reverse genetics platform. eLife. 2023;12. doi:10.7554/elife.89035
BibTeX
@article{Kipfer2023,
author = {Kipfer, Enja Tatjana and Hauser, David and Lett, Martin J and Otte, Fabian and Urda, Lorena and Zhang, Yuepeng and Lang, Christopher M R and Chami, Mohamed and Mittelholzer, Christian and Klimkait, Thomas},
title = {Rapid cloning-free mutagenesis of new SARS-CoV-2 variants using a novel reverse genetics platform},
journal = {eLife},
year = {2023},
volume = {12},
doi = {10.7554/elife.89035}
}
EUVIMED